Heartseed, Inc. (219A) AI Stock Analysis

• Market Cap: ¥43.50B
• Dividend Yield: N/A
• Average Volume (3M): 738.74K
• Price to Earnings (P/E): 72.9
• Beta (1Y): 1.28
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: JP
• Employees: 39
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 15.44
• Shares Outstanding: 22,858,200
• 10 Day Avg. Volume: 469,170
• 30 Day Avg. Volume: 738,736
• PEG Ratio: 0.83
• Price to Book (P/B): 4.62
• Price to Sales (P/S): 35.06
• P/FCF Ratio: -21.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: ¥1,361.00 ▼(-24.56% Downside)

Heartseed, Inc. faces significant challenges with profitability and cash flow management despite strong revenue growth. The technical indicators suggest a bearish trend, and the high P/E ratio points to potential overvaluation. The absence of earnings call data and corporate events limits further insights.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and successful product development, which can drive long-term business expansion and investor confidence.

Balance Sheet Health

A robust balance sheet with minimal leverage provides financial flexibility and reduces risk, supporting sustainable growth and strategic investments.

Innovative Business Model

The focus on cutting-edge regenerative medicine positions Heartseed as a leader in innovative therapies, potentially capturing significant market share in cardiovascular treatments.

Negative Factors

Profitability Challenges

Persistent negative margins highlight operational inefficiencies, which could hinder profitability and require strategic adjustments to achieve sustainable financial health.

Cash Flow Management

Negative cash flow suggests difficulties in funding operations internally, which may necessitate external financing and impact long-term financial stability.

Unprofitability

Continued unprofitability poses a risk to financial sustainability, requiring strategic initiatives to improve cost management and revenue generation.

Heartseed, Inc. Business Overview & Revenue Model

Company Description

Heartseed, Inc. engages in the provision of cardiac regenerative medicine. The company was founded by Keiichi Fukuda, Takumi Akiyama, Toshiharu Furukawa and Yutaro Kasai on November 30, 2015 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Heartseed, Inc. generates revenue primarily through the development and commercialization of its therapeutic products. The company’s revenue model includes several key streams: licensing agreements with pharmaceutical companies, grant funding for research and development, and potential milestone payments associated with clinical trial progress. Additionally, partnerships with academic institutions and healthcare organizations enhance its research capabilities and may provide funding opportunities. As the company advances its products through clinical trials and approaches regulatory approval, it stands to gain substantial financial returns from product sales and royalties.

Heartseed, Inc. Financial Statement Overview

Summary

Heartseed, Inc. shows strong revenue growth but faces challenges with profitability and cash flow management. The balance sheet is robust with minimal leverage, yet operational inefficiencies and cash flow issues pose risks.

Income Statement

Heartseed, Inc. shows a significant increase in total revenue from the previous year, demonstrating strong growth potential. However, the company faces challenges with negative EBIT and EBITDA margins, indicating operational inefficiencies. The net profit margin is also negative, reflecting ongoing unprofitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 93.7%, indicating financial stability. The debt-to-equity ratio is low at 0.001, suggesting minimal leverage risk. However, the high net loss impacts the return on equity negatively.

Cash Flow

Operating cash flow remains negative, highlighting cash management challenges. The company has a negative free cash flow, although it improved slightly from the previous year. The operating cash flow to net income ratio is below 1, suggesting inefficiencies in converting revenue into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	2.64B	873.61M	344.73M	499.06M
Gross Profit	2.61B	873.61M	344.73M	499.06M
EBITDA	610.27M	-776.36M	-1.45B	-1.41B
Net Income	519.32M	-812.73M	-1.47B	-1.41B
Balance Sheet
Total Assets	7.71B	7.07B	5.72B	4.94B
Cash, Cash Equivalents and Short-Term Investments	6.92B	5.30B	4.59B	3.99B
Total Debt	2.04M	5.39M	11.58M	30.98M
Total Liabilities	508.69M	444.35M	450.19M	208.45M
Stockholders Equity	7.20B	6.62B	5.27B	4.73B
Cash Flow
Free Cash Flow	0.00	-1.41B	-1.13B	-1.92B
Operating Cash Flow	0.00	-1.34B	-797.93M	-1.92B
Investing Cash Flow	0.00	-67.13M	-425.69M	-994.00K
Financing Cash Flow	0.00	2.12B	1.85B	-22.16M

Heartseed, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1804.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:219A, the sentiment is Negative. The current price of 1804 is below the 20-day moving average (MA) of 1960.05, below the 50-day MA of 1880.62, and below the 200-day MA of 2555.63, indicating a neutral trend. The MACD of 24.25 indicates Positive momentum. The RSI at 46.27 is Neutral, neither overbought nor oversold. The STOCH value of 6.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:219A.

Heartseed, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4595	85 Outperform	¥33.95B	11.95	―	6.29%	-12.03%	-19.61%
4552	58 Neutral	¥79.82B	-32.21	―	2.71%	7.15%	-454.41%
7774	57 Neutral	¥21.93B	-47.52	―	―	-5.65%	-469.19%
4894	55 Neutral	¥65.25B	-97.23	―	―	1772.85%	16.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
219A	45 Neutral	¥43.50B	72.89	―	―	―	―
4599	43 Neutral	¥18.18B	-9.50	―	―	―	11.34%

Heartseed, Inc. Corporate Events

Heartseed Inc. Revises Financial Forecast with Positive Outlook

Heartseed Inc. announced a revision of its full-year financial forecast for the fiscal year ending December 31, 2025, due to lower-than-expected research and development expenses. The revised forecast indicates significant improvements in operating, ordinary, and net profits, suggesting a positive financial outlook for the company.

The most recent analyst rating on (JP:219A) stock is a Hold with a Yen1361.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.

Heartseed Inc. Reports Strong Financial Recovery

Heartseed Inc. reported significant financial improvement for the twelve months ending October 31, 2025, with net sales rising to 3,026 million yen from 873 million yen the previous year. The company achieved a net profit of 592 million yen compared to a loss in the prior year, indicating a strong recovery and positive outlook for stakeholders.

The most recent analyst rating on (JP:219A) stock is a Hold with a Yen1361.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.

Heartseed, Inc. Advances Cardiac Therapy Trial After Regulatory Approval

Heartseed, Inc. announced the completion of a 30-day review by the Pharmaceuticals and Medical Devices Agency for their clinical trial notification of the HS-005 therapy, allowing the trial to commence. The EMERALD study will evaluate the safety and efficacy of this therapy in treating severe heart failure, planning to enroll 14 patients. The company plans to start patient administration in 2026, with no changes to their current earnings forecast.

The most recent analyst rating on (JP:219A) stock is a Hold with a Yen1361.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.